Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Merrimack Pharmaceuticals revenue
Merrimack Pharmaceuticals's revenue is $102.8 million.
What is Merrimack Pharmaceuticals's revenue?
- Merrimack Pharmaceuticals has 426 employees, and the revenue per employee ratio is $241,211.
- Merrimack Pharmaceuticals's peak quarterly revenue was $36.6M in 2015(q2).
- Merrimack Pharmaceuticals peak revenue was $102.8M in 2014.
On this page
Zippi applies for you, and finds you a job.
Merrimack Pharmaceuticals financial information
| CEO | Gary L. Crocker |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 426 |
| Date Founded | 2000 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $102.8M |
| Net Income | -$1,544,000 |
| PE Ratio | -49.36 |
| Tax Rate | -0.0% |
| Market Capitalization | $58.3M |
| Total Assets | $19,836,000 |
| Ticker | MACK |
Merrimack Pharmaceuticals jobs you might like
Merrimack Pharmaceuticals financing
Merrimack Pharmaceuticals received early financing of $18.3M on 2003-12-31.
| Series | Round size | Date |
|---|---|---|
| Series C | $18.3M | 12/2003 |
| Series C | $28M | 05/2004 |
| Series D | $28.3M | 04/2005 |
| Debt Financing | $9M | 06/2005 |
| Series E | $65M | 04/2006 |
| Series F | $35M | 11/2007 |
| Grant | $2.4M | 11/2010 |
| Private Equity | $77M | 04/2011 |
| Post Ipo Debt | $25M | 07/2018 |
Merrimack Pharmaceuticals investors
| Investors | Security type |
|---|---|
| GTC Biotherapeutics | Series C |
| Wharton Capital | Series C |
| Sorenson Development | Series C |
| Unilever Ventures | Series D |
| WT Investment Advisors Fund | Series D |
| Sorenson Development | Series D |
| HERCULES CAPITAL INC | Debt Financing |
| Jennison Associates | Series E |
| TPG AXON CAPITAL | Series E |
| WT Investment Advisors Fund | Series E |
| Sorenson Development | Series E |
| Crocker Ventures | Private Equity |
| Jennison Associates | Private Equity |
| TPG AXON CAPITAL | Private Equity |
| Credit Suisse | Private Equity |
| WT Investment Advisors Fund | Private Equity |
| HERCULES CAPITAL INC | Post Ipo Debt |
Merrimack Pharmaceuticals competitors
Merrimack Pharmaceuticals's top competitor, Merck, earned an annual revenue of $64.2B.
Merrimack Pharmaceuticals's smallest competitor is DURECT with revenue of $2.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 121 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Merck | $90,328 | $64.2B | 74,000 | 2,272 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Regeneron | $85,589 | $14.2B | 9,123 | 317 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 692 |
| Exelixis | $108,978 | $2.2B | 484 | 160 |
| AMRI | $76,714 | $276.6M | 3,085 | - |
| DURECT | $76,438 | $2.0M | 88 | - |
| Aradigm | $68,338 | $14.5M | 23 | - |
Merrimack Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Merrimack Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Merrimack Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Merrimack Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Merrimack Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Merrimack Pharmaceuticals. The data presented on this page does not represent the view of Merrimack Pharmaceuticals and its employees or that of Zippia.
Merrimack Pharmaceuticals may also be known as or be related to Merrimack Pharmaceuticals Inc, MERRIMACK PHARMACEUTICALS INC and Merrimack Pharmaceuticals, Inc.